Cefpodoxime Proxetil
Based on 1 Customer Validation
Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.93%
- CAS No.: 87239-81-4
- 화학식: C21H27N5O9S2
- 분자량:557.60
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Antibacterial Compound Library
HY-L049
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Animal Drug Library
HY-L218
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
All Antibiotic Isoforms
More
Biological Activity
|
β-lactam |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR male mice (19-21 g) infected with 0.2-mL portions of bacterial suspension (i.p.) [6]
-
Dosage:0.1 mL of a single-dose regimen, 0.01, 0.025, 0.1, 0.2 μg/mL
-
Administration:Oral gavage (p.o.), six dose levels or more
-
Result:Showed high protective effect against Staphylococcus aureus Smith infection (ED50 = 3.56 mg/kg).
Shows good in vivo activity against Streptococcus pneumoniae 2132 infection (ED50 = 0.57 mg/kg).
Showed high protective effect against Streptococcus pyogenes 1412 infection (ED50 = 0.16 mg/kg).
Showed potent protective effect against Escherichia coli ML4707 (ED50 = 1.38 mg/kg).
Showed good protective effect against K. pneumonia GN6445 (ED50 = 1.12 mg/kg).
Showed protective effect against Proteus mirabilis GN4754 (ED50 = 0.67 mg/kg).
Showed very porent protective effect against Serratia marcescens L-65 (ED50 = 1.31 mg/kg).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 87239-81-4
-
Appearance Solid
-
분자량 557.60
-
화학식 C21H27N5O9S2
-
Color White to light yellow
-
SMILES
O=C(C(N12)=C(COC)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)OC(OC(OC(C)C)=O)C
-
Synonyms
U-76,252; CS-807
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
용액&용해도
DMSO : 125 mg/mL (224.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Todd W. M. (1994). Cefpodoxime proxetil: a comprehensive review. International journal of antimicrobial agents, 4(1), 37–62. [Content Brief]
[2]. Date, A. A., & Nagarsenker, M. S. (2007). Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. International journal of pharmaceutics, 329(1-2), 166–172. [Content Brief]
[3]. Borin M. T. (1991). A review of the pharmacokinetics of cefpodoxime proxetil. Drugs, 42 Suppl 3, 13–21. [Content Brief]
[4]. Frampton, J. E., et al., (1992). Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs, 44(5), 889–917. [Content Brief]
[6]. Utsui, Y., et al., (1987). In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrobial agents and chemotherapy, 31(7), 1085–1092. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7934 mL | 8.9670 mL | 17.9340 mL | 44.8350 mL |
| 5 mM | 0.3587 mL | 1.7934 mL | 3.5868 mL | 8.9670 mL | |
| 10 mM | 0.1793 mL | 0.8967 mL | 1.7934 mL | 4.4835 mL | |
| 15 mM | 0.1196 mL | 0.5978 mL | 1.1956 mL | 2.9890 mL | |
| 20 mM | 0.0897 mL | 0.4484 mL | 0.8967 mL | 2.2418 mL | |
| 25 mM | 0.0717 mL | 0.3587 mL | 0.7174 mL | 1.7934 mL | |
| 30 mM | 0.0598 mL | 0.2989 mL | 0.5978 mL | 1.4945 mL | |
| 40 mM | 0.0448 mL | 0.2242 mL | 0.4484 mL | 1.1209 mL | |
| 50 mM | 0.0359 mL | 0.1793 mL | 0.3587 mL | 0.8967 mL | |
| 60 mM | 0.0299 mL | 0.1495 mL | 0.2989 mL | 0.7473 mL | |
| 80 mM | 0.0224 mL | 0.1121 mL | 0.2242 mL | 0.5604 mL | |
| 100 mM | 0.0179 mL | 0.0897 mL | 0.1793 mL | 0.4484 mL |
Cefpodoxime Proxetil Related Classifications
HY-N7101 Related Classifications
Powered by Bioz